Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Dynacil; Eliten; Fosenopril sodium; Fosinil; Fosipres; Fozitec; Monopril; NewAce; SQ 27519; SQ 28555; Staril; Tensogard; Vasopril

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Boehringer Ingelheim; Bristol-Myers Squibb; Mead Johnson; Menarini
  • Class Antihypertensives; Heart failure therapies; Imino acids; Organophosphorus compounds
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Heart failure; Hypertension
  • Discontinued Myocardial infarction

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 Feb 2013 Cefprozil sublicensed to Swedish Orphan Biovitrum in Austria, Belgium, Ireland, United Kingdom, France, Italy Germany, Spain, Finland, Sweden, Denmark, Norway, Liechtenstein, Netherlands, Portugal, and Luxembourg
  • 31 Dec 2012 Cefprozil licensed to PharmaSwiss in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top